The prognostic significance of CD20 expression in acute lymphoblastic leukemia has been investigated in children and adults and is still under debate. The aim of our study was to correlate CD20 expression with clinical-biological characteristics and outcome in 172 Philadelphia-negative patients prospectively treated in a multicenter trial introducing the molecular evaluation of minimal residual disease for therapeutic purposes. We considered 20% as the threshold for CD20 positivity. Complete remission rate, minimal residual disease negativity rate at weeks 10, 16 and 22, and disease-free and overall survival were similar among CD20 positive and negative patients, even considering minimal residual disease results and related therapeutic choices. Our study failed to demonstrate any prognostic significance for CD20 expression in Philadelphia-negative acute lymphoblastic leukemia. This conclusion is supported for the first time by a comparable minimal residual disease response rate among CD20 negative and positive patients. ClinicalTrials.gov ID, NCT00358072.

The prognostic significance of CD20 expression in acute lymphoblastic leukemia has been investigated in children and adults but is still a subject of debate. The aim of our study was to correlate CD20 expression with clinical-biological characteristics and outcome in 172 Philadelphia chromosome negative patients prospectively treated in a multicenter trial introducing the molecular evaluation of minimal residual disease for therapeutic purposes. We considered 20% as the threshold for CD20 positivity. Complete remission rate, minimal residual disease negativity rate at weeks 10, 16 and 22, and disease-free and overall survival were similar among CD20-positive and -negative patients, even considering minimal residual disease results and related therapeutic choices. Our study failed to demonstrate any prognostic significance for CD20 expression in Philadelphia chromosome negative acute lymphoblastic leukemia. This conclusion is supported for the first time by a comparable minimal residual disease response rate among CD20-positive and -negative and positive patients.

Mannelli, F., Gianfaldoni, G., Intermesoli, T., Cattaneo, C., Borlenghi, E., Cortelazzo, S., et al. (2012). CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. HAEMATOLOGICA, 97(4), 568-571 [10.3324/haematol.2011.054064].

CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease

INTERMESOLI, TAMARA;POGLIANI, ENRICO MARIA;FUMAGALLI, MONICA;
2012

Abstract

The prognostic significance of CD20 expression in acute lymphoblastic leukemia has been investigated in children and adults and is still under debate. The aim of our study was to correlate CD20 expression with clinical-biological characteristics and outcome in 172 Philadelphia-negative patients prospectively treated in a multicenter trial introducing the molecular evaluation of minimal residual disease for therapeutic purposes. We considered 20% as the threshold for CD20 positivity. Complete remission rate, minimal residual disease negativity rate at weeks 10, 16 and 22, and disease-free and overall survival were similar among CD20 positive and negative patients, even considering minimal residual disease results and related therapeutic choices. Our study failed to demonstrate any prognostic significance for CD20 expression in Philadelphia-negative acute lymphoblastic leukemia. This conclusion is supported for the first time by a comparable minimal residual disease response rate among CD20 negative and positive patients. ClinicalTrials.gov ID, NCT00358072.
No
Articolo in rivista - Articolo scientifico
Scientifica
The prognostic significance of CD20 expression in acute lymphoblastic leukemia has been investigated in children and adults but is still a subject of debate. The aim of our study was to correlate CD20 expression with clinical-biological characteristics and outcome in 172 Philadelphia chromosome negative patients prospectively treated in a multicenter trial introducing the molecular evaluation of minimal residual disease for therapeutic purposes. We considered 20% as the threshold for CD20 positivity. Complete remission rate, minimal residual disease negativity rate at weeks 10, 16 and 22, and disease-free and overall survival were similar among CD20-positive and -negative patients, even considering minimal residual disease results and related therapeutic choices. Our study failed to demonstrate any prognostic significance for CD20 expression in Philadelphia chromosome negative acute lymphoblastic leukemia. This conclusion is supported for the first time by a comparable minimal residual disease response rate among CD20-positive and -negative and positive patients.
CD20; acute lymphoblastic leukemia
Neoplasm, Residual; Philadelphia Chromosome; Young Adult; Humans; Antigens, CD20; Gene Expression; Aged; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Adult; Treatment Outcome; Middle Aged; Adolescent; Survival Analysis
English
Mannelli, F., Gianfaldoni, G., Intermesoli, T., Cattaneo, C., Borlenghi, E., Cortelazzo, S., et al. (2012). CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease. HAEMATOLOGICA, 97(4), 568-571 [10.3324/haematol.2011.054064].
Mannelli, F; Gianfaldoni, G; Intermesoli, T; Cattaneo, C; Borlenghi, E; Cortelazzo, S; Cavattoni, I; Pogliani, E; Fumagalli, M; Angelucci, E; Romani, C; Ciceri, F; Corti, C; Scattolin, A; Cortelezzi, A; Mattei, D; Audisio, E; Spinelli, O; Oldani, E; Bosi, A; Rambaldi, A; Bassan, R
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/44290
Citazioni
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 16
Social impact